AbbVie Trades at 30% EV/EBITDA Premium Over Pharma Peers
MRK•AbbVie is trading at an EV/EBITDA multiple of roughly 10.2x, about 30% above its five largest pharma peers’ 7.8x average, and at a forward P/E near 20.5x versus the group median of 16.5x. This premium valuation contrasts with comparable mid-single-digit revenue growth forecasts across the peer set, suggesting limited upside without additional catalysts.
1. Valuation Metrics
AbbVie’s enterprise value/EBITDA ratio stands at approximately 10.2x, the highest among its five largest pharma peers whose average sits at 7.8x. Its forward price/earnings multiple of around 20.5x also exceeds the peer median of 16.5x.
2. Revenue Growth Forecasts
Analysts expect AbbVie and its top peers to deliver mid-single-digit revenue growth over the next two years, driven by similar product launch pipelines and patent expiration cliffs.
3. Implications for Investors
AbbVie’s premium multiples imply limited upside at current levels unless the company can outperform growth expectations or drive further margin expansion, making relative valuation a key consideration for buyers.
